Rein Therapeutics (NASDAQ:RNTX) Director Purchases $16,747.50 in Stock

Rein Therapeutics Inc. (NASDAQ:RNTX) Director Rickenbach Josef Von purchased 15,950 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was acquired at an average cost of $1.05 per share, for a total transaction of $16,747.50. Following the purchase, the director owned 34,824 shares in the company, valued at approximately $36,565.20. The trade was a 84.51% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Rein Therapeutics Price Performance

RNTX opened at $1.11 on Friday. Rein Therapeutics Inc. has a 52 week low of $0.95 and a 52 week high of $2.18. The business has a fifty day simple moving average of $1.32 and a 200-day simple moving average of $1.31. The firm has a market cap of $94.95 million, a P/E ratio of -0.58 and a beta of 1.42.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.30. Sell-side analysts expect that Rein Therapeutics Inc. will post -1.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Rein Therapeutics to a “sell” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Rein Therapeutics currently has an average rating of “Hold” and an average price target of $8.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Voss Capital LP boosted its position in shares of Rein Therapeutics by 86.0% during the third quarter. Voss Capital LP now owns 2,666,532 shares of the company’s stock worth $3,053,000 after buying an additional 1,232,846 shares during the period. Prosight Management LP boosted its holdings in Rein Therapeutics by 32.7% in the third quarter. Prosight Management LP now owns 567,898 shares of the company’s stock valued at $650,000 after purchasing an additional 139,979 shares during the period. Gagnon Securities LLC boosted its holdings in Rein Therapeutics by 218.8% in the third quarter. Gagnon Securities LLC now owns 228,692 shares of the company’s stock valued at $262,000 after purchasing an additional 156,947 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in Rein Therapeutics in the second quarter valued at $68,000. Finally, HRT Financial LP purchased a new position in Rein Therapeutics in the fourth quarter valued at $38,000. 90.89% of the stock is currently owned by hedge funds and other institutional investors.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.